United Net Working Capital from 2010 to 2024

UTHR Stock  USD 233.85  2.10  0.89%   
United Therapeutics Net Working Capital yearly trend continues to be relatively stable with very little volatility. Net Working Capital is likely to drop to about 2.1 B. During the period from 2010 to 2024, United Therapeutics Net Working Capital destribution of quarterly values had range of 2 B from its regression line and mean deviation of  561,294,476. View All Fundamentals
 
Net Working Capital  
First Reported
2010-12-31
Previous Quarter
2.7 B
Current Value
2.1 B
Quarterly Volatility
690.7 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check United Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among United main balance sheet or income statement drivers, such as Depreciation And Amortization of 55.9 M, Total Revenue of 2.4 B or Gross Profit of 2.2 B, as well as many exotic indicators such as Price To Sales Ratio of 4.2, Dividend Yield of 0.0114 or PTB Ratio of 1.63. United financial statements analysis is a perfect complement when working with United Therapeutics Valuation or Volatility modules.
  
This module can also supplement United Therapeutics' financial leverage analysis and stock options assessment as well as various United Therapeutics Technical models . Check out the analysis of United Therapeutics Correlation against competitors.
To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.

Latest United Therapeutics' Net Working Capital Growth Pattern

Below is the plot of the Net Working Capital of United Therapeutics over the last few years. It is United Therapeutics' Net Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in United Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Working Capital10 Years Trend
Slightly volatile
   Net Working Capital   
       Timeline  

United Net Working Capital Regression Statistics

Arithmetic Mean1,512,820,857
Geometric Mean1,391,279,919
Coefficient Of Variation45.66
Mean Deviation561,294,476
Median1,003,200,000
Standard Deviation690,738,688
Sample Variance477119.9T
Range2B
R-Value0.84
Mean Square Error150411.4T
R-Squared0.71
Significance0.000086
Slope129,894,607
Total Sum of Squares6679679.1T

United Net Working Capital History

20242.1 B
20232.7 B
2022B
2021B
20201.8 B
20191.4 B
20181.5 B

About United Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include United Therapeutics income statement, its balance sheet, and the statement of cash flows. United Therapeutics investors use historical funamental indicators, such as United Therapeutics's Net Working Capital, to determine how well the company is positioned to perform in the future. Although United Therapeutics investors may use each financial statement separately, they are all related. The changes in United Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on United Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on United Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in United Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Working Capital2.7 B2.1 B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether United Therapeutics is a strong investment it is important to analyze United Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact United Therapeutics' future performance. For an informed investment choice regarding United Stock, refer to the following important reports:
Check out the analysis of United Therapeutics Correlation against competitors.
To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.
Note that the United Therapeutics information on this page should be used as a complementary analysis to other United Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

Complementary Tools for United Stock analysis

When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
FinTech Suite
Use AI to screen and filter profitable investment opportunities
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Money Managers
Screen money managers from public funds and ETFs managed around the world
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Stocks Directory
Find actively traded stocks across global markets
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Is United Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of United Therapeutics. If investors know United will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about United Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.626
Earnings Share
19.81
Revenue Per Share
49.733
Quarterly Revenue Growth
0.251
Return On Assets
0.1122
The market value of United Therapeutics is measured differently than its book value, which is the value of United that is recorded on the company's balance sheet. Investors also form their own opinion of United Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is United Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because United Therapeutics' market value can be influenced by many factors that don't directly affect United Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between United Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if United Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, United Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.